Patents by Inventor Alexander Flohr

Alexander Flohr has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190256478
    Abstract: The present invention provides compounds that are muscarinic M1 receptor positive allosteric modulators (PAM) and useful in the treatment of diseases, mediated by the muscarinic M1 receptor, such as Alzheimer's disease, cognitive impairment, schizophrenia, pain or sleep disorders, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances.
    Type: Application
    Filed: April 30, 2019
    Publication date: August 22, 2019
    Applicant: Hoffmann-La Roche Inc.
    Inventor: Alexander FLOHR
  • Publication number: 20190134050
    Abstract: The present invention provides a compound of formula I which act as inhibitors of SMAC protein binding to Inhibitor of Apoptosis Proteins (IAPs), and/or inhibitors of activated caspase protein binding to IAPs (I) their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances, alone or in combination with DR5/FAP agonist antibodies. The active compound of the present invention is useful in the amelioration, treatment or control of cancer, especially solid tumors.
    Type: Application
    Filed: May 5, 2017
    Publication date: May 9, 2019
    Inventors: Alexander FLOHR, Guido GALLEY, Roger NORCROSS, Nicolas ZORN
  • Publication number: 20180200262
    Abstract: The instant invention relates to novel conjugates of the compound of formula (I): S-L-A ??(I) or salts thereof, wherein A is a ?-secretase inhibitor, L is a linker and S is a peptidase-specific substrate, as well as processes for their manufacture, pharmaceutical compositions comprising them, and their use as medicaments.
    Type: Application
    Filed: December 11, 2017
    Publication date: July 19, 2018
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Johannes Aebi, Alexander Flohr, Juillerat-Jeanneret Lucienne, Golshayan Dela
  • Patent number: 9932335
    Abstract: The present invention relates to compounds of formula wherein R1, Y1, Y2, X, R and n are as defined herein.
    Type: Grant
    Filed: March 11, 2016
    Date of Patent: April 3, 2018
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Theresa Maria Ballard, Emmanuel Pinard, Herve Schaffhauser, Katrin Groebke Zbinden, Thomas Ryckmans, Alexander Flohr
  • Patent number: 9617271
    Abstract: The present invention relates to compounds of formula (I) and its use for the treatment of neurological disorders.
    Type: Grant
    Filed: May 6, 2015
    Date of Patent: April 11, 2017
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Alexander Flohr, Katrin Groebke Zbinden, Christian Lerner
  • Patent number: 9586970
    Abstract: The present invention relates to compounds of formula (I), wherein A, B, R1 and R2 are as defined herein before useful for the treatment of psychiatric disorders.
    Type: Grant
    Filed: May 24, 2016
    Date of Patent: March 7, 2017
    Assignee: Hoffmann-La Roche Inc.
    Inventor: Alexander Flohr
  • Patent number: 9540384
    Abstract: The invention relates to compounds of formula I wherein A1, A2, A3, B, R1, R2, R3 and R4 are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds inhibit PDE10A and can be used as medicaments.
    Type: Grant
    Filed: November 26, 2014
    Date of Patent: January 10, 2017
    Assignee: Hoffmann-La Roche, Inc.
    Inventors: Alexander Flohr, Katrin Groebke Zbinden, Matthias Koerner, Christian Lerner
  • Publication number: 20160333018
    Abstract: The present invention relates to compounds of formula I, wherein A, B, R1, R2, and Z are as defined hereinbefore.
    Type: Application
    Filed: July 27, 2016
    Publication date: November 17, 2016
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Alexander Flohr, Katrin Groebke Zbinden
  • Publication number: 20160264585
    Abstract: The present invention relates to compounds of formula (I), wherein A, B, R1 and R2 are as defined herein before useful for the treatment of psychiatric disorders.
    Type: Application
    Filed: May 24, 2016
    Publication date: September 15, 2016
    Applicant: Hoffmann-La Roche Inc.
    Inventor: Alexander Flohr
  • Patent number: 9394311
    Abstract: The present invention provides compounds of formula (Ia) and (Ib) wherein R1, R2, R3 and R4 are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds inhibit PDE10A and can be used as medicaments.
    Type: Grant
    Filed: November 25, 2014
    Date of Patent: July 19, 2016
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Alexander Flohr, Katrin Groebke Zbinden, Bernd Kuhn, Christian Lerner, Markus Rudolph, Herve Schaffhauser
  • Publication number: 20160194321
    Abstract: The present invention relates to compounds of formula wherein R1 halogen, lower alkyl, lower alkoxy, cyano, phenyl, C(O)NHCH3, C(O)NH2, lower alkyl substituted by halogen or is a five-membered heteroaryl group, optionally substituted by lower alkyl; Y1 is N or CH; Y2 is CH; and if Y1 is CH, Y1 and Y2 may form together with the C-atoms to which they are attached a ring, containing —CH?N—N(CH3)—, —CH?N—N(H)—; X is CH or N; R is (CH2)m-cycloalkyl, optionally substituted by hydroxy, lower alkoxy or lower alkyl, or is tetrahydropyran, optionally substituted by hydroxy, or is lower alkoxy, substituted by hydroxy, or is lower alkyl substituted by one or two hydroxy, or is (CH2)m-pyridinyl, optionally substituted by hydroxy, lower alkyl or lower alkyl substituted by hydroxy, or is L-phenyl, optionally substituted by hydroxy, lower alkyl or lower alkyl substituted by hydroxy, and L is a bond, —CH(CH2OH)— or —CH2CH(OH)—; n is 0, 1 or 2; m is 0 or 1; or to a pharmaceutically acceptable acid addition salt, to
    Type: Application
    Filed: March 11, 2016
    Publication date: July 7, 2016
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Theresa Maria BALLARD, Emmanuel PINARD, Herve SCHAFFHAUSER, Katrin GROEBKE ZBINDEN, Thomas RYCKMANS, Alexander FLOHR
  • Publication number: 20160031878
    Abstract: The present invention relates to radiolabeled compounds of formula I wherein R1, R2, R3 and R4 are as defined herein.
    Type: Application
    Filed: July 30, 2015
    Publication date: February 4, 2016
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Edilio BORRONI, Alexander FLOHR, Luca GOBBI, Thomas HARTUNG, Raphael HOAREAU, Michael HONER, Laurent MARTARELLO
  • Patent number: 9227970
    Abstract: The invention is concerned with triazolopyridine compounds of formula (I) wherein R1, R2 and R3 are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds inhibit PDE10A and can be used as medicaments.
    Type: Grant
    Filed: December 16, 2014
    Date of Patent: January 5, 2016
    Assignee: Hoffmann-La Roche, Inc.
    Inventors: Alexander Flohr, Katrin Groebke Zbinden, Matthias Koerner
  • Publication number: 20150274661
    Abstract: The present invention provides compounds of formula (I), wherein Z, R1, R2, and R3 are as described herein, as well as pharmaceutically acceptable salts and esters thereof. Further the present invention is concerned with the manufacture of the compounds of formula (I), pharmaceutical compositions comprising them and their use as medicaments for the treatment of Alzheimer's disease.
    Type: Application
    Filed: October 15, 2013
    Publication date: October 1, 2015
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Karlheinz Baumann, Alexander Flohr, Synese Jolidon, Henner Knust, Thomas Luebbers, Matthias Nettekoven
  • Patent number: 9115130
    Abstract: The invention relates to a novel process for the preparation of 2-phenyl-[1,2,4]triazolo[1,5-a]pyridine derivatives of formula I or of a salt thereof wherein R1 stands for hydrogen, a halogen, for an optionally protected hydroxyl group or for an optionally protected amino group and R2 is hydrogen or a halogen. 2-Phenyl-[1,2,4]triazolo[1,5-a]pyridine derivatives of formula I with their 1,2,4-triazole nucleus build the structural core of a great number of functionalized molecules in medicinal chemistry.
    Type: Grant
    Filed: August 8, 2014
    Date of Patent: August 25, 2015
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Bjoern Bartels, Serena Maria Fantasia, Alexander Flohr, Kurt Puentener, Shaoning Wang
  • Publication number: 20150232472
    Abstract: The present invention relates to compounds of formula (I) and its use for the treatment of neurological disorders.
    Type: Application
    Filed: May 6, 2015
    Publication date: August 20, 2015
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventors: Alexander Flohr, Katrin Groebke Zbinden, Christian Lerner
  • Publication number: 20150148332
    Abstract: The present invention provides compounds of formula (Ia) and (Ib) wherein R1, R2, R3 and R4 are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds inhibit PDE10A and can be used as medicaments.
    Type: Application
    Filed: November 25, 2014
    Publication date: May 28, 2015
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventors: Alexander Flohr, Katrin Groebke Zbinden, Bernd Kuhn, Christian Lerner, Markus Rudolph, Herve Schaffhauser
  • Publication number: 20150099735
    Abstract: The invention is concerned with triazolopyridine compounds of formula (I) wherein R1, R2 and R3 are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds inhibit PDE10A and can be used as medicaments.
    Type: Application
    Filed: December 16, 2014
    Publication date: April 9, 2015
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Alexander Flohr, Katrin Groebke Zbinden, Matthias Koerner
  • Publication number: 20150087644
    Abstract: The invention relates to compounds of formula I wherein A1, A2, A3, B, R1, R2, R3 and R4 are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds inhibit PDE10A and can be used as medicaments.
    Type: Application
    Filed: November 26, 2014
    Publication date: March 26, 2015
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventors: Alexander Flohr, Katrin Groebke Zbinden, Matthias Koerner, Christian Lerner
  • Patent number: 8962834
    Abstract: The invention relates to compounds of formula wherein the substituents are as described in claim 1. Compounds of formula I are modulators for amyloid beta and thus, they may be useful for the treatment or prevention of a disease associated with the deposition of ?-amyloid in the brain, in particular Alzheimer's disease, and other diseases such as cerebral amyloid angiopathy, hereditary cerebral hemorrhage with amyloidosis, Dutch-type (HCHWA-D), multi-infarct dementia, dementia pugilistica and Down syndrome.
    Type: Grant
    Filed: January 25, 2013
    Date of Patent: February 24, 2015
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Karlheinz Baumann, Alexander Flohr, Erwin Goetschi, Helmut Jacobsen, Synese Jolidon, Thomas Luebbers